Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02854761
Recruitment Status : Unknown
Verified August 2016 by Efranat Ltd..
Recruitment status was:  Not yet recruiting
First Posted : August 3, 2016
Last Update Posted : August 3, 2016
Information provided by (Responsible Party):
Efranat Ltd.

Brief Summary:
This study evaluates the safety and tolerability of the investigational drug EF-022 in the treatment of adult patients with Recurrent Respiratory Papillomatosis (RRP). Patients will be administered EF-022, either intramuscular or subcutaneous, for a period of 6 months. Preliminary effect of the drug on the disease will be evaluated by following the number and severity of the lesions in the respiratory tract and the effect on voice changes.

Condition or disease Intervention/treatment Phase
Recurrent Respiratory Papillomatosis Drug: EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) Phase 1

Detailed Description:

The etiology of RRP is associated with local immune suppression at disease-involved sites.

EF-022, a Vitamin D-Binding protein Macrophage Activating Factor, modulates the innate arm of the immune system to alleviate immune suppression. The investigators hypothesize that EF-022 may modulate the immune response in a manner that might slow down or even prevent disease progression.

Adult subjects will be treated weekly with EF-022 for a period of 6 months by either intramuscular or subcutaneous administration.

The primary objective of the study is to evaluate the safety and tolerability of EF-022 administered to adult subjects with recurrent respiratory papillomatosis either IM or SC.

The main response assessment will be performed over the 6 months period by:

  • Evaluating lesion size and/or number of disease-involved sites by Coltera-Derkay score
  • Assessment of degree of voice disorder using the VHI-10 score
  • Symptomatic assessment of dyspnea/stridor

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Safety and Tolerability Study of EF-022 in Adult Subjects With Recurrent Respiratory Papillomatosis
Study Start Date : September 2016
Estimated Primary Completion Date : September 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Vitamin D

Arm Intervention/treatment
Experimental: SC administration
Subcutaneous (SC) administration of 500 ng of EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly, for 6 months
Drug: EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)
Experimental: IM administration
Intramuscular (IM) adminstration of 500 ng EF-022 (Modified Vitamin D Binding Protein Macrophage Activator) once weekly for 6 months
Drug: EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)

Primary Outcome Measures :
  1. CTCAE v.4.03 criteria will constitute the primary safety endpoints to be monitored throughout this study [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with documented diagnosis of recurrent respiratory papillomatosis
  2. Patients with measurable disease
  3. Patients presenting at least one of the following severity criteria: Derkay score ≥ 8 , Voice handicap index (VHI) ≥11
  4. Adult male and female subjects, age of 18 and above (≥18 yrs)
  5. Patients with documentation on number of debulking procedures done during past 12 months
  6. Estimated expectancy time for next debulking procedure must be at least 3 months.
  7. Must be at least 4 weeks (>4 weeks) since last treatment including cytotoxic therapy, biological or immunotherapy, anti-viral therapy, molecularly targeted therapy or steroid treatment.
  8. Must be at least 2 weeks (>2weeks) since last NSAID treatment.
  9. Must have adequately recovered (to at least Grade 1 level) from adverse effects of prior therapies.
  10. Female of child bearing potential must have a negative pregnancy test and must be practicing an effective method of birth control
  11. Patients or their guardians must sign an informed consent indicating that they are aware of the investigational nature of this study

Exclusion Criteria:

  1. Patient on concurrent steroids or anti-inflammatory non steroid treatment.
  2. Active autoimmune disease
  3. Known major immunodeficiency
  4. Known to be Positive for HIV, Hepatitis B surface antigen, Hepatitis C antibody
  5. Have absolute neutrophil counts below 1.5X 10^9/L
  6. Hemoglobin below 10.0 g/dL
  7. White blood cell counts below 3.5X10^9/L.
  8. Granulocytes below 1.5X10^9/L.
  9. Have Platelets below 100 X 10^9/L
  10. Abnormal renal function with creatinine above 1.5X the upper limit of normal (ULN)
  11. Abnormal liver function tests with bilirubin above 1.5X the ULN, AST and ALT above 2.5 X ULN.
  12. Patients with active cardiovascular disease under continuous treatment
  13. Patients with associated malignancy currently receiving chemotherapy and/or radiation.
  14. Female adult patients that are pregnant, nursing or plan to nurse during and up to 12 months of treatment period.
  15. Subjects receiving another investigational drug.
  16. Patients with concurrent or history of malignancy within 5 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02854761

Contact: Myriam Golembo, PhD 972-8-9724972
Contact: Uri Yogev 972-8-9724972

Sponsors and Collaborators
Efranat Ltd.

Responsible Party: Efranat Ltd. Identifier: NCT02854761     History of Changes
Other Study ID Numbers: CS-102
First Posted: August 3, 2016    Key Record Dates
Last Update Posted: August 3, 2016
Last Verified: August 2016

Additional relevant MeSH terms:
Respiratory Tract Infections
Papillomavirus Infections
Neoplasms, Squamous Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Respiratory Tract Diseases
DNA Virus Infections
Virus Diseases
Tumor Virus Infections
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents